Peptides for post-cancer hormonal changes

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Cancer treatments, while life-saving, frequently disrupt the delicate balance of the endocrine system, leading to significant hormonal changes.. Up to 70% of cancer survivors experience some form of hormonal imbalance, impacting quality of life, energy levels, and overall well-being [National Cancer Institute, 2024].

Cancer treatments, while life-saving, frequently disrupt the delicate balance of the endocrine system, leading to significant hormonal changes. Up to 70% of cancer survivors experience some form of hormonal imbalance, impacting quality of life, energy levels, and overall well-being [National Cancer Institute, 2024]. Addressing these changes with targeted peptide therapies and hormone replacement strategies can be crucial for recovery.

Testosterone Replacement Therapy (TRT) in Cancer Survivors

For male cancer survivors, particularly those treated for prostate cancer, concerns about testosterone replacement therapy (TRT) are common. Historically, there was apprehension that TRT could fuel prostate cancer growth. However, recent evidence challenges this long-held belief. Multiple studies, including those reviewed by the Mayo Clinic and published in PMC, suggest that TRT does not increase the risk of new prostate cancer development or recurrence [Mayo Clinic, 2025; Morgentaler, 2015]. In fact, some clinicians now consider TRT safe for men who have had metastatic prostate cancer in the past, especially when aiming to restore quality of life [YouTube, 2023].

When considering TRT, a typical starting dose might be 50-100 mg of testosterone cypionate or enanthate injected intramuscularly weekly or bi-weekly, or daily transdermal gels. Regular monitoring of total and free testosterone, PSA, and hematocrit levels is essential, typically every 3-6 months initially, then annually [American Urological Association, 2023].

Growth Hormone-Releasing Peptides (GHRPs): Ipamorelin and Sermorelin

Growth hormone deficiency (GHD) is a common sequela of cancer treatments, particularly radiation to the head and neck or pituitary surgery. GHD can manifest as fatigue, reduced muscle mass, increased adiposity, and impaired cognitive function. Growth hormone-releasing peptides (GHRPs) like Ipamorelin and Sermorelin stimulate the body’s natural production of growth hormone (GH).

Ipamorelin, a selective GHRP, stimulates the pituitary gland to release GH without significantly impacting cortisol or prolactin levels, offering a cleaner physiological response [Svensson et al., 2000]. Sermorelin, a growth hormone-releasing hormone (GHRH) analog, also promotes natural GH secretion. For adults, a common dosage for Ipamorelin is 200-300 mcg subcutaneously once daily, typically before bedtime to align with natural GH pulsatility [Walker, 2022]. Sermorelin dosages often range from 200-500 mcg subcutaneously daily. Both aim to restore more youthful GH patterns, improving body composition, energy, and overall vitality.

Nuance and Considerations: GH and Cancer Risk

While GHRPs stimulate endogenous GH, the broader topic of GH replacement in cancer survivors requires careful consideration. A consensus statement from the European Journal of Endocrinology (Boguszewski et al., 2022) concluded that current evidence does not support an association between GH replacement and primary tumor or cancer recurrence when used appropriately. However, the interplay between GH, insulin-like growth factor-1 (IGF-1), and cancer development is complex. Elevated IGF-1 levels have been implicated in the progression of certain cancers, such as breast cancer [PharmacyTimes, 2015]. Therefore, while GHRPs can be beneficial, their use should be carefully monitored, especially in patients with a history of hormone-sensitive cancers, ensuring that IGF-1 levels remain within a safe physiological range.

Comparison: TRT vs. GHRPs

The primary distinction between TRT and GHRPs lies in their target hormones and mechanisms. TRT directly replaces testosterone, addressing androgen deficiency. Its safety profile in cancer survivors, particularly those with prostate cancer history, has been increasingly validated, suggesting that fear of recurrence may be overstated for many. GHRPs, conversely, stimulate the body's own GH production, indirectly influencing a cascade of anabolic and regenerative processes. While both aim to restore hormonal balance and improve quality of life, the oncological considerations differ. TRT's direct replacement is generally considered safe for many cancer survivors, whereas GHRPs, by influencing the GH/IGF-1 axis, require more nuanced monitoring due to the complex relationship between IGF-1 and certain cancer types. The choice between them, or their combined use, hinges on a thorough endocrine evaluation and oncological risk assessment.

Clinical Takeaway

Managing post-cancer hormonal changes requires a personalized and evidence-based approach. For male survivors with testosterone deficiency, TRT can be a safe and effective option, with modern data largely alleviating concerns about cancer recurrence; initiate with 50-100 mg testosterone cypionate weekly, monitoring PSA and testosterone levels. For those with growth hormone deficiency, GHRPs like Ipamorelin (200-300 mcg nightly) or Sermorelin (200-500 mcg nightly) can restore physiological GH pulsatility. However, always monitor IGF-1 levels closely when using GHRPs, especially in patients with a history of hormone-sensitive cancers, to ensure benefits outweigh any theoretical risks. A comprehensive endocrine workup and ongoing oncological surveillance are paramount for safe and effective hormonal optimization.

References